<Summary id="CDR0000368374" LegacyPDQID="" ReplacementFor="CDR0000062721"><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Patients</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Myeloproliferative neoplasms treatments vary and depend upon the specific diagnosis. Treatment may include observation, phlebotomy, transfusions, chemotherapy/medications, radiation, immunotherapy, targeted therapy, and stem cell transplant. Learn more in this expert-reviewed summary.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq">Myeloproliferative Neoplasms (PDQ®): Treatment</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/myeloproliferative/hp/myeloproliferative-neoplasms-treatment">Myeloproliferative Neoplasms (PDQ®): Treatment</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028327">PDQ Adult Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000039347">chronic myeloproliferative neoplasms</TermRef></MainTopics><SummaryAbstract><Para id="_347">This PDQ cancer information summary has current information about the treatment of myeloproliferative neoplasms. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.</Para><Para id="_348">Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Date Last Modified") is the date of the most recent change. The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the PDQ Adult Treatment Editorial Board.</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>chronic eosinophilic leukemia
</SummaryKeyWord><SummaryKeyWord>chronic myeloproliferative neoplasms</SummaryKeyWord><SummaryKeyWord>chronic neutrophilic leukemia</SummaryKeyWord><SummaryKeyWord>essential thrombocythemia</SummaryKeyWord><SummaryKeyWord>polycythemia vera</SummaryKeyWord><SummaryKeyWord>primary myelofibrosis</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version</SummaryTitle><AltTitle TitleType="Browser">Myeloproliferative Neoplasms Treatment</AltTitle><AltTitle TitleType="CancerTypeHomePage">Myeloproliferative Neoplasms Treatment</AltTitle><SummarySection id="_1"><Title>General Information About Myeloproliferative Neoplasms</Title><SummarySection id="_2"><SectMetaData><SectionType>Cancer description</SectionType><SectionType>Organ description</SectionType></SectMetaData><KeyPoint id="_3">Myeloproliferative neoplasms are a group of diseases in which the bone marrow makes too many red blood cells, white blood cells, or platelets.</KeyPoint><Para id="_127">Normally, the <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> makes <GlossaryTermRef href="CDR0000765906" dictionary="Cancer.gov" audience="Patient">blood stem cells</GlossaryTermRef> (immature cells) that become mature blood cells over time.</Para><MediaLink ref="CDR0000755927" type="image/jpeg" alt="Anatomy of the bone; drawing shows spongy bone, red marrow, and yellow marrow. A cross section of the bone shows compact bone and blood vessels in the bone marrow. Also shown are red blood cells, white blood cells, platelets, and a blood stem cell." language="en" placement="image-center" id="_345"><Caption language="en">Anatomy of the bone. The bone is made up of compact bone, spongy bone, and bone marrow. Compact bone makes up the outer layer of the bone. Spongy bone is found mostly at the ends of bones and contains red marrow. Bone marrow is found in the center of most bones and has many blood vessels. There are two types of bone marrow: red and yellow. Red marrow contains blood stem cells that can become red blood cells, white blood cells, or platelets. Yellow marrow is made mostly of fat.</Caption></MediaLink><Para id="_344">A blood stem cell may become a <GlossaryTermRef href="CDR0000046279" dictionary="Cancer.gov" audience="Patient">myeloid</GlossaryTermRef> <GlossaryTermRef href="CDR0000046598" dictionary="Cancer.gov" audience="Patient">stem cell</GlossaryTermRef> or a <GlossaryTermRef href="CDR0000046298" dictionary="Cancer.gov" audience="Patient">lymphoid</GlossaryTermRef> stem cell. A lymphoid stem cell becomes a <GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">white blood cell</GlossaryTermRef>. A myeloid stem cell becomes one of three types of mature blood cells:</Para><ItemizedList id="_128" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000046124" dictionary="Cancer.gov" audience="Patient">red blood cells</GlossaryTermRef> that carry <GlossaryTermRef href="CDR0000538149" dictionary="Cancer.gov" audience="Patient">oxygen</GlossaryTermRef> and other substances to all
			 tissues of the body</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000046374" dictionary="Cancer.gov" audience="Patient">granulocytes</GlossaryTermRef>, which are white blood cells that help fight <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infection</GlossaryTermRef> and disease</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000045840" dictionary="Cancer.gov" audience="Patient">platelets</GlossaryTermRef> that form <GlossaryTermRef href="CDR0000476017" dictionary="Cancer.gov" audience="Patient">blood clots</GlossaryTermRef> to stop bleeding</ListItem></ItemizedList><MediaLink ref="CDR0000526219" type="image/jpeg" alt="Blood cell development; drawing shows the steps a blood stem cell goes through to become a red blood cell, platelet, or white blood cell. Drawing shows a myeloid stem cell becoming a red blood cell, platelet, or myeloblast, which then becomes a white blood cell. Drawing also shows a lymphoid stem cell becoming a lymphoblast and then one of several different types of white blood cells." language="en" placement="image-center" id="_302"><Caption language="en">Blood cell development. A blood stem cell goes through several steps to become a red blood cell, platelet, or white blood cell.</Caption></MediaLink><Para id="_139"> In <GlossaryTermRef href="CDR0000045210" dictionary="Cancer.gov" audience="Patient">myeloproliferative neoplasms</GlossaryTermRef>,  too many blood stem cells become one or more types of  blood cells. The neoplasms usually get worse slowly as the number of extra blood cells increases.</Para></SummarySection><SummarySection id="_24"><SectMetaData><SectionType>Cancer description</SectionType></SectMetaData><KeyPoint id="_25">The following are types of myeloproliferative neoplasms.</KeyPoint><Para id="_140">The type of  myeloproliferative neoplasm is based on whether too many red blood cells, white blood cells, or platelets are being made.  Sometimes the body will make too many of more than one type of blood cell, but usually one type of blood cell is affected more than the others are. <GlossaryTermRef href="CDR0000752241" dictionary="Cancer.gov" audience="Patient">Myeloproliferative neoplasms</GlossaryTermRef> include:</Para><ItemizedList id="_138" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000046755" dictionary="Cancer.gov" audience="Patient">chronic myeloid leukemia</GlossaryTermRef></ListItem><ListItem><GlossaryTermRef href="CDR0000426418" dictionary="Cancer.gov" audience="Patient">polycythemia vera</GlossaryTermRef></ListItem><ListItem><GlossaryTermRef href="CDR0000256562" dictionary="Cancer.gov" audience="Patient">essential thrombocythemia</GlossaryTermRef></ListItem><ListItem>vert and prefibrotic <GlossaryTermRef href="CDR0000306488" dictionary="Cancer.gov" audience="Patient">primary myelofibrosis</GlossaryTermRef> (also called chronic idiopathic myelofibrosis)</ListItem><ListItem><GlossaryTermRef href="CDR0000426409" dictionary="Cancer.gov" audience="Patient">chronic neutrophilic leukemia</GlossaryTermRef></ListItem><ListItem><GlossaryTermRef href="CDR0000426408" dictionary="Cancer.gov" audience="Patient">chronic eosinophilic leukemia</GlossaryTermRef></ListItem><ListItem>myeloproliferative neoplasms unclassifiable</ListItem></ItemizedList><Para id="_141">These types are described below.  Myeloproliferative neoplasms sometimes become <GlossaryTermRef href="CDR0000045145" dictionary="Cancer.gov" audience="Patient">acute leukemia</GlossaryTermRef>, in which too many
<GlossaryTermRef href="CDR0000044636" dictionary="Cancer.gov" audience="Patient">abnormal</GlossaryTermRef> white blood cells are made.</Para></SummarySection><SummarySection id="_198"><SectMetaData><SectionType>Diagnostic tests</SectionType></SectMetaData><KeyPoint id="_213">Tests that examine the blood and bone marrow are used to diagnose myeloproliferative neoplasms.</KeyPoint><Para id="_161">In addition to asking about your <GlossaryTermRef href="CDR0000642019" dictionary="Cancer.gov" audience="Patient">personal</GlossaryTermRef> and <GlossaryTermRef href="CDR0000642015" dictionary="Cancer.gov" audience="Patient">family health history</GlossaryTermRef> and doing a <GlossaryTermRef href="CDR0000270871" dictionary="Cancer.gov" audience="Patient">physical exam</GlossaryTermRef>, your doctor may perform the following tests and procedures:</Para><ItemizedList id="_162" Style="bullet"><ListItem><Strong><GlossaryTermRef href="CDR0000729979" dictionary="Cancer.gov" audience="Patient">Complete blood count (CBC) with differential</GlossaryTermRef></Strong> checks a sample of blood for:  
   <ItemizedList id="_166" Style="dash"><ListItem>the number of red blood cells and platelets</ListItem><ListItem>the number and type of white blood cells</ListItem><ListItem>the amount of <GlossaryTermRef href="CDR0000045108" dictionary="Cancer.gov" audience="Patient">hemoglobin</GlossaryTermRef> (the <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">protein</GlossaryTermRef> that carries oxygen) in the red blood cells 
   </ListItem><ListItem>the amount of hematocrit (whole blood that is made up of red blood cells)</ListItem></ItemizedList><MediaLink ref="CDR0000526546" type="image/jpeg" alt="Complete blood count (CBC); left panel shows blood being drawn from a vein on the inside of the elbow using a tube attached to a syringe; right panel shows a laboratory test tube with blood cells separated into layers: plasma, white blood cells, platelets, and red blood cells." language="en" placement="image-center" id="_293"><Caption language="en">Complete blood count (CBC). Blood is collected by inserting a needle into a vein and allowing the blood to flow into a tube. The blood sample is sent to the laboratory and the red blood cells, white blood cells, and platelets are counted.  The CBC is used to test for, diagnose, and monitor many different conditions.</Caption></MediaLink></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000390307" dictionary="Cancer.gov" audience="Patient">Peripheral blood smear</GlossaryTermRef></Strong> checks a sample of blood for: <ItemizedList id="_332" Style="dash"><ListItem>whether there are  red blood cells shaped like teardrops</ListItem><ListItem>the number and kinds of white blood cells</ListItem><ListItem>the number of platelets</ListItem><ListItem>whether there are <GlossaryTermRef href="CDR0000046503" dictionary="Cancer.gov" audience="Patient">blast</GlossaryTermRef> cells</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000304685" dictionary="Cancer.gov" audience="Patient">Blood chemistry study</GlossaryTermRef></Strong> uses a blood sample to measure the amounts of certain substances released into the blood by organs and tissues in the body. An unusual amount of a substance can be a sign of disease.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000669655" dictionary="Cancer.gov" audience="Patient">Bone marrow aspiration and biopsy</GlossaryTermRef></Strong> is the removal of bone marrow, blood, and a small piece of bone by inserting a hollow needle into the hipbone or <GlossaryTermRef href="CDR0000549425" dictionary="Cancer.gov" audience="Patient">breastbone</GlossaryTermRef>. A <GlossaryTermRef href="CDR0000046244" dictionary="Cancer.gov" audience="Patient">pathologist</GlossaryTermRef> views the bone marrow, blood, and bone under a microscope to look for abnormal cells.<MediaLink ref="CDR0000554337" type="image/jpeg" alt="Bone marrow aspiration and biopsy; drawing shows a patient lying face down on a table and a bone marrow needle being inserted into the hip bone. An inset shows a close up of the needle being inserted through the skin and hip bone into the bone marrow." language="en" placement="image-center" id="_342"><Caption language="en">Bone marrow aspiration and biopsy. After a small area of skin is numbed, a long, hollow needle is inserted through the patient's skin and hip bone into the bone marrow. A sample of bone marrow and a small piece of bone are removed for examination under a microscope.</Caption></MediaLink></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000270737" dictionary="Cancer.gov" audience="Patient">Cytogenetic analysis</GlossaryTermRef></Strong> checks the <GlossaryTermRef href="CDR0000046470" dictionary="Cancer.gov" audience="Patient">chromosomes</GlossaryTermRef> of cells in a sample of bone marrow, blood, tumor, or other tissue for broken, missing, rearranged, or extra chromosomes. Changes in certain chromosomes may be a sign of <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>. Cytogenetic analysis is used to help diagnose cancer, plan treatment, or find out how well treatment is working.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046128" dictionary="Cancer.gov" audience="Patient">Genetic testing</GlossaryTermRef></Strong> is done on a bone marrow or blood sample to check for mutations in <GeneName><GlossaryTermRef href="CDR0000775969" dictionary="Cancer.gov" audience="Patient">JAK2</GlossaryTermRef></GeneName>, <GeneName><GlossaryTermRef href="CDR0000776821" dictionary="Cancer.gov" audience="Patient">MPL</GlossaryTermRef></GeneName>, or <GeneName><GlossaryTermRef href="CDR0000776823" dictionary="Cancer.gov" audience="Patient">CALR</GlossaryTermRef></GeneName> genes. A <GeneName>JAK2</GeneName> gene mutation is often found in patients with polycythemia vera, essential thrombocythemia, or primary myelofibrosis. <GeneName>MPL</GeneName> or <GeneName>CALR</GeneName> gene mutations are found in patients with essential thrombocythemia or primary myelofibrosis.</ListItem> </ItemizedList></SummarySection></SummarySection><SummarySection id="_222"><Title>Chronic Myeloid Leukemia</Title><Para id="_224"><GlossaryTermRef href="CDR0000046755" dictionary="Cancer.gov" audience="Patient">Chronic myeloid leukemia</GlossaryTermRef> is a disease in which too many <GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">white blood cells</GlossaryTermRef> are made in the <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef>. To learn more about <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosis</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046597" dictionary="Cancer.gov" audience="Patient">staging</GlossaryTermRef>, and treatment, visit <SummaryRef href="CDR0000258006" url="/types/leukemia/patient/cml-treatment-pdq">Chronic Myeloid Leukemia Treatment</SummaryRef>.</Para></SummarySection><SummarySection id="_225"><Title>Polycythemia Vera</Title><SummarySection id="_276"><KeyPoint id="_226">Polycythemia vera is a disease in which too many red blood cells are made in the bone marrow.</KeyPoint><Para id="_227">In <GlossaryTermRef href="CDR0000426418" dictionary="Cancer.gov" audience="Patient">polycythemia vera</GlossaryTermRef>, the blood becomes thickened with too many <GlossaryTermRef href="CDR0000046124" dictionary="Cancer.gov" audience="Patient">red blood cells</GlossaryTermRef>. The number of <GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">white blood cells</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045840" dictionary="Cancer.gov" audience="Patient">platelets</GlossaryTermRef> may also increase. These extra blood cells may collect in the <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef> and cause it to swell.  The increased number of red blood cells, white blood cells, or platelets in the blood can cause bleeding problems and make clots form in <GlossaryTermRef href="CDR0000045020" dictionary="Cancer.gov" audience="Patient">blood vessels</GlossaryTermRef>. This can increase the risk of <GlossaryTermRef href="CDR0000439425" dictionary="Cancer.gov" audience="Patient">stroke</GlossaryTermRef> or heart attack.  In patients who are older than 65 years or who have a history of  <GlossaryTermRef href="CDR0000476017" dictionary="Cancer.gov" audience="Patient">blood clots</GlossaryTermRef>, the risk of stroke or heart attack  is higher. Patients also have an increased risk of <GlossaryTermRef href="CDR0000046347" dictionary="Cancer.gov" audience="Patient">acute myeloid leukemia</GlossaryTermRef> or <GlossaryTermRef href="CDR0000306488" dictionary="Cancer.gov" audience="Patient">primary myelofibrosis</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_277"><KeyPoint id="_228">Symptoms of polycythemia vera include headaches and a feeling of fullness below the ribs on the left side.</KeyPoint><Para id="_229">Polycythemia vera often does not cause early <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef>. It may be found during a routine <GlossaryTermRef href="CDR0000045107" dictionary="Cancer.gov" audience="Patient">blood test</GlossaryTermRef>. Signs and symptoms may occur as the number of blood cells increases. Other conditions may cause the same signs and symptoms. Check with your doctor if you have:</Para><ItemizedList id="_230" Style="bullet"><ListItem>a feeling of pressure or fullness below the ribs on the left side</ListItem><ListItem>headaches</ListItem><ListItem>double vision or seeing dark or blind spots that come and go</ListItem><ListItem>itching all over the body, especially after being in warm or hot water</ListItem><ListItem>reddened face that looks like a blush or sunburn</ListItem><ListItem>weakness</ListItem><ListItem>dizziness</ListItem><ListItem>weight loss for no known reason</ListItem></ItemizedList></SummarySection><SummarySection id="_278"><KeyPoint id="_231">Special blood tests are used to diagnose polycythemia vera.</KeyPoint><Para id="_232">In addition to a <GlossaryTermRef href="CDR0000045107" dictionary="Cancer.gov" audience="Patient">complete blood count</GlossaryTermRef>, <GlossaryTermRef href="CDR0000669655" dictionary="Cancer.gov" audience="Patient">bone marrow aspiration and biopsy</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000270737" dictionary="Cancer.gov" audience="Patient">cytogenetic analysis</GlossaryTermRef>, a <GlossaryTermRef href="CDR0000044088" dictionary="Cancer.gov" audience="Patient">serum</GlossaryTermRef> <GlossaryTermRef href="CDR0000045958" dictionary="Cancer.gov" audience="Patient">erythropoietin</GlossaryTermRef> test is used to diagnose polycythemia vera. In this test, a sample of blood is checked for the level of erythropoietin (a <GlossaryTermRef href="CDR0000045713" dictionary="Cancer.gov" audience="Patient">hormone</GlossaryTermRef> that stimulates new red blood cells to be made). In polycythemia vera, the erythropoietin level would be lower than normal because the body does not need to make more red blood cells. </Para></SummarySection></SummarySection><SummarySection id="_382"><Title>Essential Thrombocythemia</Title><SummarySection id="_283"><KeyPoint id="_246">Essential thrombocythemia is a disease in which too many platelets are made in the bone marrow.</KeyPoint><Para id="_247"><GlossaryTermRef href="CDR0000256562" dictionary="Cancer.gov" audience="Patient">Essential thrombocythemia</GlossaryTermRef> causes an <GlossaryTermRef href="CDR0000044636" dictionary="Cancer.gov" audience="Patient">abnormal</GlossaryTermRef> increase in the number of <GlossaryTermRef href="CDR0000045840" dictionary="Cancer.gov" audience="Patient">platelets</GlossaryTermRef> made in the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_284"><KeyPoint id="_248">Patients with essential thrombocythemia may have no signs or symptoms.</KeyPoint><Para id="_249">Essential thrombocythemia often does not cause early <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef>. It may be found during a routine <GlossaryTermRef href="CDR0000045107" dictionary="Cancer.gov" audience="Patient">blood test</GlossaryTermRef>. Signs and symptoms may be caused by essential thrombocythemia or by other conditions.  Check with your doctor if you have:</Para><ItemizedList id="_250" Style="bullet"><ListItem>headaches</ListItem><ListItem>burning or tingling in the hands or feet</ListItem><ListItem>redness and warmth of the hands or feet</ListItem><ListItem>vision or hearing problems</ListItem></ItemizedList><Para id="_251">Platelets are sticky. When there are too many platelets, they may clump together and make it hard for the blood to flow.  Clots may form in <GlossaryTermRef href="CDR0000045020" dictionary="Cancer.gov" audience="Patient">blood vessels</GlossaryTermRef> and there may also be increased bleeding. These can cause serious health problems such as <GlossaryTermRef href="CDR0000439425" dictionary="Cancer.gov" audience="Patient">stroke</GlossaryTermRef> and heart attack, or <GlossaryTermRef href="CDR0000800034" dictionary="Cancer.gov" audience="Patient">pulmonary embolism</GlossaryTermRef> and  <GlossaryTermRef href="CDR0000640038" dictionary="Cancer.gov" audience="Patient">deep
vein thrombosis</GlossaryTermRef> in people older than 60 years, who have had blood clots 
or high white blood cell counts in the past. In some people, essential thrombocythemia may become acute leukemia.</Para></SummarySection><SummarySection id="_285"><KeyPoint id="_252">Certain factors affect prognosis (chance of recovery) and treatment options for essential thrombocythemia.</KeyPoint><Para id="_253"><GlossaryTermRef href="CDR0000045849" dictionary="Cancer.gov" audience="Patient">Prognosis</GlossaryTermRef> and treatment options depend on:</Para><ItemizedList id="_254" Style="bullet"><ListItem>the age of the patient</ListItem><ListItem>whether the patient has signs or symptoms or other problems related to essential thrombocythemia</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_234"><Title>Overt and Prefibrotic Primary Myelofibrosis</Title><SummarySection id="_279"><KeyPoint id="_235">Primary myelofibrosis is a disease in which abnormal blood cells and fibers build up inside the bone marrow.</KeyPoint><Para id="_236">The <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> is made of tissues that make blood cells (<GlossaryTermRef href="CDR0000046124" dictionary="Cancer.gov" audience="Patient">red blood cells</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">white blood cells</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000045840" dictionary="Cancer.gov" audience="Patient">platelets</GlossaryTermRef>) and a web of fibers that support the blood-forming tissues.  In <GlossaryTermRef href="CDR0000306488" dictionary="Cancer.gov" audience="Patient">primary myelofibrosis</GlossaryTermRef> (also called chronic idiopathic myelofibrosis), large numbers of <GlossaryTermRef href="CDR0000765906" dictionary="Cancer.gov" audience="Patient">blood stem cells</GlossaryTermRef> become blood cells that do not mature properly (<GlossaryTermRef href="CDR0000046503" dictionary="Cancer.gov" audience="Patient">blasts</GlossaryTermRef>). The web of fibers inside the bone marrow also becomes very thick (like <GlossaryTermRef href="CDR0000640078" dictionary="Cancer.gov" audience="Patient">scar tissue</GlossaryTermRef>) and slows the blood-forming tissue’s ability to make blood cells.  This causes the blood-forming tissues to make fewer and fewer blood cells.  In order to make up for the low number of blood cells made in the bone marrow, the <GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">liver</GlossaryTermRef> and <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef> begin to make the blood cells.</Para></SummarySection><SummarySection id="_280"><KeyPoint id="_237">Symptoms of primary myelofibrosis include pain below the ribs on the left side and feeling very tired.</KeyPoint><Para id="_238">Primary myelofibrosis often does not cause early <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef>. It may be found during a routine <GlossaryTermRef href="CDR0000045107" dictionary="Cancer.gov" audience="Patient">blood test</GlossaryTermRef>. Signs and symptoms may be caused by primary myelofibrosis or by other conditions. Check with your doctor if you have:</Para><ItemizedList id="_239" Style="bullet"><ListItem>pain or a feeling of fullness below the ribs on the left side</ListItem><ListItem>early satiety (feeling full sooner than normal when eating)</ListItem><ListItem><GlossaryTermRef href="CDR0000045360" dictionary="Cancer.gov" audience="Patient">anemia</GlossaryTermRef></ListItem><ListItem>bone pain</ListItem><ListItem>tiredness</ListItem><ListItem>shortness of breath</ListItem><ListItem>easy bruising or bleeding</ListItem><ListItem><GlossaryTermRef href="CDR0000046236" dictionary="Cancer.gov" audience="Patient">petechiae</GlossaryTermRef> (flat, red, pinpoint spots under the skin that are caused by bleeding)</ListItem><ListItem><GlossaryTermRef href="CDR0000450108" dictionary="Cancer.gov" audience="Patient">fever</GlossaryTermRef></ListItem><ListItem>drenching night sweats</ListItem><ListItem>weight loss</ListItem></ItemizedList></SummarySection><SummarySection id="_282"><KeyPoint id="_242">Certain factors affect prognosis (chance of recovery) and treatment options for  primary myelofibrosis.</KeyPoint><Para id="_243">The <GlossaryTermRef href="CDR0000045849" dictionary="Cancer.gov" audience="Patient">prognosis</GlossaryTermRef> depends on:</Para><ItemizedList id="_244" Style="bullet"><ListItem>the age of the patient</ListItem><ListItem>the number of <GlossaryTermRef href="CDR0000044636" dictionary="Cancer.gov" audience="Patient">abnormal</GlossaryTermRef> red blood cells and white blood cells</ListItem><ListItem>the number of blasts in the blood</ListItem><ListItem>whether there are certain changes in the <GlossaryTermRef href="CDR0000046470" dictionary="Cancer.gov" audience="Patient">chromosomes</GlossaryTermRef></ListItem><ListItem>whether the patient has signs such as fever, drenching night sweats, or weight loss</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_255"><Title>Chronic Neutrophilic Leukemia</Title><Para id="_257"><GlossaryTermRef href="CDR0000426409" dictionary="Cancer.gov" audience="Patient">Chronic neutrophilic leukemia</GlossaryTermRef> is a disease in which too many <GlossaryTermRef href="CDR0000765906" dictionary="Cancer.gov" audience="Patient">blood stem cells</GlossaryTermRef> become a type of <GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">white blood cell</GlossaryTermRef> called <GlossaryTermRef href="CDR0000046270" dictionary="Cancer.gov" audience="Patient">neutrophils</GlossaryTermRef>. Neutrophils are <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infection</GlossaryTermRef>-fighting blood cells that surround and destroy dead cells and <GlossaryTermRef href="CDR0000698772" dictionary="Cancer.gov" audience="Patient">foreign</GlossaryTermRef> substances (such as <GlossaryTermRef href="CDR0000044123" dictionary="Cancer.gov" audience="Patient">bacteria</GlossaryTermRef>). The <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef> and <GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">liver</GlossaryTermRef> may swell because of the extra neutrophils. Chronic neutrophilic leukemia may stay the same or it may progress quickly to <GlossaryTermRef href="CDR0000045145" dictionary="Cancer.gov" audience="Patient">acute leukemia</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_258"><Title>Chronic Eosinophilic Leukemia</Title><SummarySection id="_286"><KeyPoint id="_259">Chronic eosinophilic leukemia is a disease in which  too many white blood cells (eosinophils) are made in the bone marrow.</KeyPoint><Para id="_260"><GlossaryTermRef href="CDR0000044844" dictionary="Cancer.gov" audience="Patient">Eosinophils</GlossaryTermRef> are <GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">white blood cells</GlossaryTermRef> that react to allergens (substances that cause an <GlossaryTermRef href="CDR0000443292" dictionary="Cancer.gov" audience="Patient">allergic response</GlossaryTermRef>) and help fight <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infections</GlossaryTermRef> caused by certain <GlossaryTermRef href="CDR0000044310" dictionary="Cancer.gov" audience="Patient">parasites</GlossaryTermRef>. In <GlossaryTermRef href="CDR0000426408" dictionary="Cancer.gov" audience="Patient">chronic eosinophilic leukemia</GlossaryTermRef>, there are too many eosinophils in the blood, <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef>, and other tissues. Chronic eosinophilic leukemia may stay the same for many years or it may progress quickly to <GlossaryTermRef href="CDR0000045145" dictionary="Cancer.gov" audience="Patient">acute leukemia</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_287"><KeyPoint id="_261">Signs and symptoms of chronic eosinophilic leukemia include fever and feeling very tired.</KeyPoint><Para id="_262">Chronic eosinophilic leukemia may not cause early <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef>. It may be found during a routine <GlossaryTermRef href="CDR0000045107" dictionary="Cancer.gov" audience="Patient">blood test</GlossaryTermRef>. Signs and symptoms may be caused by chronic eosinophilic leukemia or by other <GlossaryTermRef href="CDR0000651193" dictionary="Cancer.gov" audience="Patient">conditions</GlossaryTermRef>. Check with your doctor if you have:</Para><ItemizedList id="_263" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000450108" dictionary="Cancer.gov" audience="Patient">fever</GlossaryTermRef></ListItem><ListItem>tiredness</ListItem><ListItem>cough</ListItem><ListItem>swelling under the skin around the eyes and lips, in the <GlossaryTermRef href="CDR0000439429" dictionary="Cancer.gov" audience="Patient">throat</GlossaryTermRef>, or on the hands and feet</ListItem><ListItem>muscle pain</ListItem><ListItem>itching</ListItem><ListItem><GlossaryTermRef href="CDR0000306496" dictionary="Cancer.gov" audience="Patient">diarrhea</GlossaryTermRef></ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_20"><Title>Stages of Myeloproliferative Neoplasms</Title><SummarySection id="_307"><KeyPoint id="_308">There is no standard staging system for myeloproliferative neoplasms.</KeyPoint><Para id="_309">The process used to find out if cancer has spread to other parts of the body is called <GlossaryTermRef href="CDR0000046597" dictionary="Cancer.gov" audience="Patient">staging</GlossaryTermRef>. There is no standard <GlossaryTermRef href="CDR0000689095" dictionary="Cancer.gov" audience="Patient">staging system</GlossaryTermRef> for <GlossaryTermRef href="CDR0000752241" dictionary="Cancer.gov" audience="Patient">myeloproliferative neoplasms</GlossaryTermRef>.  It
		  is important to know the type of myeloproliferative neoplasm in order to plan treatment.</Para></SummarySection></SummarySection><SummarySection id="_28"><Title>Treatment Option Overview</Title><SummarySection id="_29"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_30">There are different types of treatment for patients with myeloproliferative neoplasms.</KeyPoint><Para id="_31">Different types of treatments are available for patients with <GlossaryTermRef href="CDR0000752241" dictionary="Cancer.gov" audience="Patient">myeloproliferative neoplasms</GlossaryTermRef>. Some treatments are <GlossaryTermRef href="CDR0000044930" dictionary="Cancer.gov" audience="Patient">standard</GlossaryTermRef> (the currently used treatment), and some are being tested in <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trials</GlossaryTermRef>. A treatment clinical trial is a <GlossaryTermRef href="CDR0000651211" dictionary="Cancer.gov" audience="Patient">research study</GlossaryTermRef> meant to help improve current treatments or obtain information on new treatments. When clinical trials show that a new treatment is better than the  standard treatment, the new treatment may become the standard treatment.    Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.</Para></SummarySection><SummarySection id="_33"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_34">The following types of treatment are used:</KeyPoint><SummarySection id="_264"><KeyPoint id="_265">Watchful waiting</KeyPoint><Para id="_266"><GlossaryTermRef href="CDR0000045942" dictionary="Cancer.gov" audience="Patient">Watchful waiting</GlossaryTermRef> is closely <GlossaryTermRef href="CDR0000454803" dictionary="Cancer.gov" audience="Patient">monitoring</GlossaryTermRef> a patient’s condition without giving any treatment until <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> appear or change.</Para></SummarySection><SummarySection id="_38"><KeyPoint id="_39">
     Phlebotomy</KeyPoint><Para id="_40"><GlossaryTermRef href="CDR0000256580" dictionary="Cancer.gov" audience="Patient">Phlebotomy</GlossaryTermRef> is a procedure in which blood is taken from a vein. A sample of blood may be taken  for tests such as a <GlossaryTermRef href="CDR0000044649" dictionary="Cancer.gov" audience="Patient">CBC</GlossaryTermRef> or <GlossaryTermRef href="CDR0000304685" dictionary="Cancer.gov" audience="Patient">blood chemistry</GlossaryTermRef>. Sometimes phlebotomy is used as a treatment and blood is taken from the body to remove extra <GlossaryTermRef href="CDR0000046124" dictionary="Cancer.gov" audience="Patient">red blood cells</GlossaryTermRef>. Phlebotomy is used in this way to treat some myeloproliferative neoplasms.</Para></SummarySection><SummarySection id="_218"><KeyPoint id="_219">
     Platelet apheresis</KeyPoint><Para id="_220">Platelet apheresis is a treatment that uses a special machine to remove  <GlossaryTermRef href="CDR0000045840" dictionary="Cancer.gov" audience="Patient">platelets</GlossaryTermRef> from the blood. Blood is taken from the patient and put through a blood cell separator where the platelets are removed. The rest of the blood is then returned to the patient’s bloodstream.</Para></SummarySection><SummarySection id="_267"><KeyPoint id="_268">Transfusion therapy</KeyPoint><Para id="_269"><GlossaryTermRef href="CDR0000045991" dictionary="Cancer.gov" audience="Patient">Blood transfusion</GlossaryTermRef> is a method of giving red blood cells, <GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">white blood cells</GlossaryTermRef>, or platelets to replace blood cells destroyed by disease or cancer treatment.</Para></SummarySection><SummarySection id="_35"><KeyPoint id="_36">
     Chemotherapy</KeyPoint><Para id="_37"><GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">Chemotherapy</GlossaryTermRef> is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them  from dividing.   When chemotherapy is taken by mouth or <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injected</GlossaryTermRef> into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (<GlossaryTermRef href="CDR0000301626" dictionary="Cancer.gov" audience="Patient">systemic chemotherapy</GlossaryTermRef>).</Para><Para id="_316"> Learn more at <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/myeloproliferative-neoplasms">Drugs Approved for Myeloproliferative Neoplasms</ExternalRef>.</Para></SummarySection><SummarySection id="_44"><KeyPoint id="_45">
     Radiation therapy
    </KeyPoint><Para id="_46"><GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">Radiation therapy</GlossaryTermRef> is a cancer treatment that uses high-energy <GlossaryTermRef href="CDR0000045944" dictionary="Cancer.gov" audience="Patient">x-rays</GlossaryTermRef> or other types of <GlossaryTermRef href="CDR0000045072" dictionary="Cancer.gov" audience="Patient">radiation</GlossaryTermRef> to kill cancer cells or keep them from growing. <GlossaryTermRef href="CDR0000046686" dictionary="Cancer.gov" audience="Patient">External radiation therapy</GlossaryTermRef> uses a machine outside the body to send radiation toward the area of the body, such as the <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef>, with cancer.</Para></SummarySection><SummarySection id="_270"><KeyPoint id="_271">Other drug therapy</KeyPoint><Para id="_335"><DrugRef href="CDR0000652391" url="/about-cancer/treatment/drugs/prednisone">Prednisone</DrugRef> and <GlossaryTermRef href="CDR0000045188" dictionary="Cancer.gov" audience="Patient">danazol</GlossaryTermRef> are drugs that may be used to treat <GlossaryTermRef href="CDR0000045360" dictionary="Cancer.gov" audience="Patient">anemia</GlossaryTermRef> in patients with <GlossaryTermRef href="CDR0000306488" dictionary="Cancer.gov" audience="Patient">primary myelofibrosis</GlossaryTermRef>.</Para><Para id="_272"><GlossaryTermRef href="CDR0000302451" dictionary="Cancer.gov" audience="Patient">Anagrelide</GlossaryTermRef> therapy is used to reduce the risk of <GlossaryTermRef href="CDR0000476017" dictionary="Cancer.gov" audience="Patient">blood clots</GlossaryTermRef> in patients who have too many platelets in 
their blood. Low-dose <GlossaryTermRef href="CDR0000045176" dictionary="Cancer.gov" audience="Patient">aspirin</GlossaryTermRef> may also be used to reduce the risk of blood clots.</Para><Para id="_310"><DrugRef href="CDR0000496418" url="/about-cancer/treatment/drugs/thalidomide">Thalidomide</DrugRef>, <DrugRef href="CDR0000492044" url="/about-cancer/treatment/drugs/lenalidomide">lenalidomide</DrugRef>, and <DrugRef href="CDR0000746335" url="/about-cancer/treatment/drugs/pomalidomide">pomalidomide</DrugRef> are drugs that prevent <GlossaryTermRef href="CDR0000045020" dictionary="Cancer.gov" audience="Patient">blood vessels</GlossaryTermRef> from growing into areas of tumor cells.</Para><Para id="_354"><GlossaryTermRef href="CDR0000045958" dictionary="Cancer.gov" audience="Patient">Erythropoietic</GlossaryTermRef> <GlossaryTermRef href="CDR0000045705" dictionary="Cancer.gov" audience="Patient">growth factors</GlossaryTermRef>    are used to stimulate the <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> to make red blood cells.</Para><Para id="_317"> Learn more at <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/myeloproliferative-neoplasms">Drugs Approved for Myeloproliferative Neoplasms</ExternalRef>.</Para></SummarySection><SummarySection id="_50"><KeyPoint id="_51">
     Surgery
    </KeyPoint><Para id="_52">Splenectomy (surgery to remove the spleen) may be done if the spleen is enlarged.</Para></SummarySection><SummarySection id="_55"><KeyPoint id="_56">Immunotherapy</KeyPoint><Para id="_57"><GlossaryTermRef href="CDR0000045729" dictionary="Cancer.gov" audience="Patient">Immunotherapy</GlossaryTermRef> is a treatment that uses the patient's <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune system</GlossaryTermRef> to fight cancer.  Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer. </Para><ItemizedList id="_355" Style="bullet"><ListItem>Interferon: Interferon affects the division of cancer cells and can slow tumor growth. <DrugRef href="CDR0000744420" url="/about-cancer/treatment/drugs/recombinant-interferon-alfa-2b">Interferon alfa</DrugRef> and <GlossaryTermRef href="CDR0000346467" dictionary="Cancer.gov" audience="Patient">pegylated interferon alpha</GlossaryTermRef> are commonly used to treat certain myeloproliferative neoplasms.</ListItem></ItemizedList></SummarySection><SummarySection id="_336"><KeyPoint id="_337">Targeted therapy</KeyPoint><Para id="_338"><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells.</Para><ItemizedList id="_356" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000044833" dictionary="Cancer.gov" audience="Patient">Tyrosine kinase inhibitor</GlossaryTermRef> (TKI) therapy: TKI therapy blocks signals that cancer cells need to grow. <DrugRef href="CDR0000717928" url="/about-cancer/treatment/drugs/ruxolitinibphosphate">Ruxolitinib</DrugRef>  is used to treat <GlossaryTermRef href="CDR0000426418" dictionary="Cancer.gov" audience="Patient">polycythemia vera</GlossaryTermRef>  and certain types of <GlossaryTermRef href="CDR0000045947" dictionary="Cancer.gov" audience="Patient">myelofibrosis</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_343">Learn more at <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/myeloproliferative-neoplasms">Drugs Approved for Myeloproliferative Neoplasms</ExternalRef>.</Para><Para id="_340">Other types of targeted therapies are being studied in clinical trials.</Para></SummarySection><SummarySection id="_273"><KeyPoint id="_274">High-dose chemotherapy with stem cell transplant</KeyPoint><Para id="_275">High doses of chemotherapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">Stem cell transplant</GlossaryTermRef> is a treatment to replace the blood-forming cells. <GlossaryTermRef href="CDR0000046598" dictionary="Cancer.gov" audience="Patient">Stem cells</GlossaryTermRef> (immature blood cells) are removed from the blood or bone marrow of the patient or a <GlossaryTermRef href="CDR0000643010" dictionary="Cancer.gov" audience="Patient">donor</GlossaryTermRef> and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusion</GlossaryTermRef>. These reinfused stem cells grow into (and restore) the body's blood cells. <MediaLink ref="CDR0000765030" type="image/jpeg" alt="Donor stem cell transplant; (Panel 1): Drawing of stem cells being collected from a donor's bloodstream using an apheresis machine. Blood is removed from a vein in the donor's arm and flows through the machine where the stem cells are removed. The rest of the blood is then returned to the donor through a vein in their other arm. (Panel 2): Drawing of a health care provider giving a patient an infusion of chemotherapy through a catheter in the patient's chest. The chemotherapy is given to kill cancer cells and prepare the patient's body for the donor stem cells. (Panel 3): Drawing of a patient receiving an infusion of the donor stem cells through a catheter in the chest." language="en" placement="image-center" id="_346"><Caption language="en">Donor stem cell transplant. (Step 1): Four to five days before donor stem cell collection, the donor receives a medicine to increase the number of stem cells circulating through their bloodstream (not shown). The blood-forming stem cells are then collected from the donor through a large vein in their arm. The blood flows through an apheresis machine that removes the stem cells. The rest of the blood is returned to the donor through a vein in their other arm. (Step 2): The patient receives chemotherapy to kill cancer cells and prepare their body for the donor stem cells. The patient may also receive radiation therapy (not shown). (Step 3): The patient receives an infusion of the donor stem cells.</Caption></MediaLink></Para></SummarySection></SummarySection><SummarySection id="_53"><SectMetaData><SectionType>Treatment in clinical trials</SectionType></SectMetaData><KeyPoint id="_54">New types of treatment are being tested in clinical trials.</KeyPoint><Para id="_53_md_3">For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.</Para><Para id="_53_md_4">You can use the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the <ExternalRef xref="https://clinicaltrials.gov/">ClinicalTrials.gov</ExternalRef> website.</Para><Para id="_53_md_5">Learn more about clinical trials, including how to find and join one, at <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">Clinical Trials Information for Patients and Caregivers</ExternalRef>.</Para></SummarySection><SummarySection id="_351"><KeyPoint id="_352">Treatment for myeloproliferative neoplasms may cause side effects.</KeyPoint><Para id="_351_md_73">For information about <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> caused by treatment for cancer, visit our <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/side-effects">Side Effects</ExternalRef> page.</Para></SummarySection><SummarySection id="_300"><KeyPoint id="_301">Follow-up care may be needed.</KeyPoint><Para id="_300_md_33">As you go through treatment, you  will have follow-up tests or check-ups. Some tests that were done to <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnose</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stage</GlossaryTermRef> the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.</Para><Para id="_300_md_34">Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back). </Para></SummarySection></SummarySection><SummarySection id="_357"><SectMetaData><SpecificDiagnosis ref="CDR0000039350">polycythemia vera</SpecificDiagnosis></SectMetaData><Title>Treatment of Chronic Myeloid Leukemia</Title><Para id="_358">Learn more at <SummaryRef href="CDR0000258006" url="/types/leukemia/patient/cml-treatment-pdq">Chronic Myeloid Leukemia Treatment</SummaryRef>.</Para><Para id="_TrialSearch_357_19">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef>  about clinical trials is also available.</Para></SummarySection><SummarySection id="_359"><SectMetaData><SpecificDiagnosis ref="CDR0000039350">polycythemia vera</SpecificDiagnosis></SectMetaData><Title>Treatment of Polycythemia Vera</Title><Para id="_361">The purpose of treatment for <GlossaryTermRef href="CDR0000426418" dictionary="Cancer.gov" audience="Patient">polycythemia vera</GlossaryTermRef> is to reduce the number of extra blood cells.  Treatment of polycythemia vera may include:</Para><ItemizedList id="_362" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000256580" dictionary="Cancer.gov" audience="Patient">phlebotomy</GlossaryTermRef></ListItem>
    <ListItem><GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> (<DrugRef href="CDR0000780126" url="/about-cancer/treatment/drugs/hydroxyurea">hydroxyurea</DrugRef>)  with or without  phlebotomy</ListItem><ListItem><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">targeted therapy</GlossaryTermRef> (<DrugRef href="CDR0000717928" url="/about-cancer/treatment/drugs/ruxolitinibphosphate">ruxolitinib</DrugRef>), if the chemotherapy does not work</ListItem><ListItem><GlossaryTermRef href="CDR0000045729" dictionary="Cancer.gov" audience="Patient">immunotherapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000346467" dictionary="Cancer.gov" audience="Patient">pegylated interferon alpha</GlossaryTermRef> or <DrugRef href="CDR0000806960" url="/about-cancer/treatment/drugs/ropeginterferon-alfa-2b-njft">ropeginterferon alfa-2B</DrugRef>)</ListItem>
    <ListItem>low-dose <GlossaryTermRef href="CDR0000045176" dictionary="Cancer.gov" audience="Patient">aspirin</GlossaryTermRef></ListItem></ItemizedList><Para id="_384">Learn more about these treatments in the <SummaryRef href="CDR0000368374#_33" url="/types/myeloproliferative/patient/chronic-treatment-pdq">Treatment Option Overview</SummaryRef>.</Para><Para id="_TrialSearch_359_19">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef>  about clinical trials is also available.</Para></SummarySection><SummarySection id="_383"><SectMetaData><SpecificDiagnosis ref="CDR0000039361">essential thrombocythemia</SpecificDiagnosis></SectMetaData><Title>Treatment of Essential Thrombocythemia</Title><Para id="_372">Treatment of <GlossaryTermRef href="CDR0000256562" dictionary="Cancer.gov" audience="Patient">essential thrombocythemia</GlossaryTermRef> in patients younger than 60  years who have no <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> and an acceptable  <GlossaryTermRef href="CDR0000045840" dictionary="Cancer.gov" audience="Patient">platelet</GlossaryTermRef> count is usually <GlossaryTermRef href="CDR0000045942" dictionary="Cancer.gov" audience="Patient">watchful waiting</GlossaryTermRef>. Treatment of other patients may include:</Para><ItemizedList id="_373" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> (<DrugRef href="CDR0000780126" url="/about-cancer/treatment/drugs/hydroxyurea">hydroxyurea</DrugRef>)</ListItem><ListItem><GlossaryTermRef href="CDR0000045729" dictionary="Cancer.gov" audience="Patient">immunotherapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045324" dictionary="Cancer.gov" audience="Patient">interferon alfa</GlossaryTermRef> or <GlossaryTermRef href="CDR0000346467" dictionary="Cancer.gov" audience="Patient">pegylated interferon alpha</GlossaryTermRef>)</ListItem><ListItem><GlossaryTermRef href="CDR0000302451" dictionary="Cancer.gov" audience="Patient">anagrelide</GlossaryTermRef></ListItem>
    
    </ItemizedList><Para id="_385">Learn more about these treatments in the <SummaryRef href="CDR0000368374#_33" url="/types/myeloproliferative/patient/chronic-treatment-pdq">Treatment Option Overview</SummaryRef>.</Para><Para id="_TrialSearch_383_19">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef>  about clinical trials is also available.</Para></SummarySection><SummarySection id="_363"><SectMetaData><SpecificDiagnosis ref="CDR0000039357">primary myelofibrosis</SpecificDiagnosis></SectMetaData><Title>Treatment of Primary Myelofibrosis</Title><Para id="_365">Treatment of <GlossaryTermRef href="CDR0000306488" dictionary="Cancer.gov" audience="Patient">primary myelofibrosis</GlossaryTermRef> in patients without <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> is usually <GlossaryTermRef href="CDR0000045942" dictionary="Cancer.gov" audience="Patient">watchful waiting</GlossaryTermRef>.</Para><Para id="_366">Patients with primary myelofibrosis may have signs or symptoms of <GlossaryTermRef href="CDR0000045360" dictionary="Cancer.gov" audience="Patient">anemia</GlossaryTermRef>. Anemia is usually treated with <GlossaryTermRef href="CDR0000046001" dictionary="Cancer.gov" audience="Patient">transfusion</GlossaryTermRef> of <GlossaryTermRef href="CDR0000046124" dictionary="Cancer.gov" audience="Patient">red blood cells</GlossaryTermRef> to relieve symptoms and improve <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>. In addition, anemia may be treated with:</Para><ItemizedList id="_367" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045958" dictionary="Cancer.gov" audience="Patient">erythropoietic</GlossaryTermRef> <GlossaryTermRef href="CDR0000045705" dictionary="Cancer.gov" audience="Patient">growth factors</GlossaryTermRef></ListItem><ListItem><DrugRef href="CDR0000652391" url="/about-cancer/treatment/drugs/prednisone">prednisone</DrugRef></ListItem><ListItem><GlossaryTermRef href="CDR0000045188" dictionary="Cancer.gov" audience="Patient">danazol</GlossaryTermRef></ListItem><ListItem><DrugRef href="CDR0000496418" url="/about-cancer/treatment/drugs/thalidomide">thalidomide</DrugRef>, <DrugRef href="CDR0000492044" url="/about-cancer/treatment/drugs/lenalidomide">lenalidomide</DrugRef>, or <DrugRef href="CDR0000746335" url="/about-cancer/treatment/drugs/pomalidomide">pomalidomide</DrugRef>, with or without prednisone</ListItem></ItemizedList><Para id="_368">Treatment of primary myelofibrosis in patients with other signs or symptoms may include:</Para><ItemizedList id="_369" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">targeted therapy</GlossaryTermRef> with <DrugRef href="CDR0000717928" url="/about-cancer/treatment/drugs/ruxolitinibphosphate">ruxolitinib</DrugRef></ListItem><ListItem><GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> (hydroxyurea, cladribine)</ListItem><ListItem><GlossaryTermRef href="CDR0000270732" dictionary="Cancer.gov" audience="Patient">allogeneic stem cell transplant</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045114" dictionary="Cancer.gov" audience="Patient">bone marrow transplant</GlossaryTermRef></ListItem><ListItem>thalidomide, lenalidomide, or pomalidomide</ListItem>
    
    
   <ListItem><GlossaryTermRef href="CDR0000046594" dictionary="Cancer.gov" audience="Patient">splenectomy</GlossaryTermRef></ListItem><ListItem><GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy</GlossaryTermRef> to the <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef>, or other areas outside the <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> where blood cells are forming</ListItem><ListItem><GlossaryTermRef href="CDR0000045729" dictionary="Cancer.gov" audience="Patient">immunotherapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045324" dictionary="Cancer.gov" audience="Patient">interferon alfa</GlossaryTermRef>)</ListItem></ItemizedList><Para id="_386">Learn more about these treatments in the <SummaryRef href="CDR0000368374#_33" url="/types/myeloproliferative/patient/chronic-treatment-pdq">Treatment Option Overview</SummaryRef>.</Para><Para id="_TrialSearch_363_19">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef>  about clinical trials is also available.</Para></SummarySection><SummarySection id="_374"><SectMetaData><SpecificDiagnosis ref="CDR0000276485">chronic neutrophilic leukemia</SpecificDiagnosis></SectMetaData><Title>Treatment of Chronic Neutrophilic Leukemia</Title><Para id="_376">Treatment of <GlossaryTermRef href="CDR0000426409" dictionary="Cancer.gov" audience="Patient">chronic neutrophilic leukemia</GlossaryTermRef> may include:</Para><ItemizedList id="_377" Style="bullet"><ListItem> <GlossaryTermRef href="CDR0000045114" dictionary="Cancer.gov" audience="Patient">allogenic bone marrow transplant</GlossaryTermRef></ListItem><ListItem><GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef></ListItem><ListItem><GlossaryTermRef href="CDR0000045729" dictionary="Cancer.gov" audience="Patient">immunotherapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045324" dictionary="Cancer.gov" audience="Patient">interferon alfa</GlossaryTermRef>)</ListItem>
    
    </ItemizedList><Para id="_387">Learn more about these treatments in the <SummaryRef href="CDR0000368374#_33" url="/types/myeloproliferative/patient/chronic-treatment-pdq">Treatment Option Overview</SummaryRef>.</Para><Para id="_TrialSearch_374_19">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef>  about clinical trials is also available.</Para></SummarySection><SummarySection id="_378"><SectMetaData><SpecificDiagnosis ref="CDR0000276487">chronic eosinophilic leukemia</SpecificDiagnosis></SectMetaData><Title>Treatment of Chronic Eosinophilic Leukemia</Title><Para id="_380">Treatment of <GlossaryTermRef href="CDR0000426408" dictionary="Cancer.gov" audience="Patient">chronic eosinophilic leukemia</GlossaryTermRef> may include:</Para><ItemizedList id="_381" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045263" dictionary="Cancer.gov" audience="Patient">bone marrow transplant</GlossaryTermRef></ListItem><ListItem><GlossaryTermRef href="CDR0000045729" dictionary="Cancer.gov" audience="Patient">immunotherapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045324" dictionary="Cancer.gov" audience="Patient">interferon alfa</GlossaryTermRef>)</ListItem>
    
    </ItemizedList><Para id="_388">Learn more about these treatments in the <SummaryRef href="CDR0000368374#_33" url="/types/myeloproliferative/patient/chronic-treatment-pdq">Treatment Option Overview</SummaryRef>.</Para><Para id="_TrialSearch_378_19">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef>  about clinical trials is also available.</Para></SummarySection><SummarySection id="_290"><Title>To Learn More About Myeloproliferative Neoplasms</Title><Para id="_291">For more information from the <GlossaryTermRef href="CDR0000044266" dictionary="Cancer.gov" audience="Patient">National Cancer Institute</GlossaryTermRef> about  myeloproliferative neoplasms, visit:</Para><ItemizedList id="_319" Style="bullet"><ListItem><ExternalRef xref="https://www.cancer.gov/types/myeloproliferative">Myeloproliferative Neoplasms Home Page</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/myeloproliferative-neoplasms">Drugs Approved for Myeloproliferative Neoplasms</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy">Immunotherapy to Treat Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant">Stem Cell Transplants in Cancer Treatment</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></ListItem></ItemizedList><Para id="_290_md_40">For general cancer information and other resources from the National Cancer Institute, visit:</Para><ItemizedList id="_290_md_41" Style="bullet"><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer">About Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/diagnosis-staging/staging">Cancer Staging</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/publications/patient-education/chemo-and-you">Chemotherapy and You: Support for People With Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/publications/patient-education/radiation-therapy-and-you">Radiation Therapy and You: Support for People With Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/coping">Coping with Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/coping/questions">Questions to Ask Your Doctor about Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://cancercontrol.cancer.gov/ocs/resources/survivors.html">For Survivors, Caregivers, and Advocates</ExternalRef></ListItem></ItemizedList></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>About PDQ</Title><Para id="_AboutThis_3">Physician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in <ExternalRef xref="https://www.cancer.gov/espanol/publicaciones/pdq">Spanish</ExternalRef>.</Para><Para id="_AboutThis_4">PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government’s center of biomedical research.  The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.</Para></SummarySection><SummarySection id="_AboutThis_5"><Title>Purpose of This Summary</Title><Para id="_AboutThis_6">This PDQ cancer information summary has current information about the treatment of myeloproliferative neoplasms.  It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.</Para></SummarySection><SummarySection id="_AboutThis_7"><Title>Reviewers and Updates</Title><Para id="_AboutThis_8">Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Updated") is the date of the most recent change.
</Para><Para id="_AboutThis_9">The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>.
</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Clinical Trial Information</Title><Para id="_AboutThis_11">A clinical trial is a study to answer a scientific question, such as whether one treatment is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. During treatment clinical trials, information is collected about the effects of a new treatment and how well it works. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
</Para><Para id="_AboutThis_12">Clinical trials can be found online at <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI's website</ExternalRef>. For more information, call the <ExternalRef xref="https://www.cancer.gov/contact/contact-center">Cancer Information Service</ExternalRef> (CIS), NCI's contact center, at 1-800-4-CANCER (1-800-422-6237).
</Para></SummarySection><SummarySection id="_AboutThis_13"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_14">PDQ is a registered trademark. The content of PDQ documents can be used freely as text. It cannot be identified as an NCI PDQ cancer information summary unless the whole summary is shown and it is updated regularly. However, a user would be allowed to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks in the following way: [include excerpt from the summary].”
</Para><Para id="_AboutThis_15">The best way to cite this PDQ summary is:</Para><Para id="_AboutThis_21">PDQ® Adult Treatment Editorial Board. PDQ Myeloproliferative Neoplasms Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq">https://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389435]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use in the PDQ summaries only. If you want to use an image from a PDQ summary and you are not using the whole summary, you must get permission from the owner. It cannot be given by the National Cancer Institute. Information about using the images in this summary, along with many other images related to cancer can be found in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>. Visuals Online is a collection of more than 3,000 scientific images.
</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">The information in these summaries should not be used to make decisions about insurance reimbursement. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_19"><Title>Contact Us</Title><Para id="_AboutThis_20">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">E-mail Us</ExternalRef>.</Para></SummarySection></SummarySection><PatientVersionOf ref="CDR0000062927"/><DateFirstPublished>2005-01-24</DateFirstPublished><DateLastModified>2025-05-12</DateLastModified></Summary>
